Literature DB >> 32576590

Tiragolumab Impresses in Multiple Trials.

.   

Abstract

The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung cancer. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 32576590     DOI： 10.1158/2159-8290.CD-NB2020-063

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  11 in total

Review 1.  Signal pathways and precision therapy of small-cell lung cancer.

Authors:  Min Yuan; Yu Zhao; Hendrik-Tobias Arkenau; Tongnei Lao; Li Chu; Qing Xu
Journal:  Signal Transduct Target Ther       Date:  2022-06-15

Review 2.  Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?

Authors:  Robert W Lentz; Meryl D Colton; Siddhartha S Mitra; Wells A Messersmith
Journal:  Mol Cancer Ther       Date:  2021-04-13       Impact factor: 6.009

3.  Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer.

Authors:  Marina Martinez; Soyeon Kim; Naomi St Jean; Shaun O'Brien; Lurong Lian; Jing Sun; Raluca I Verona; Edmund Moon
Journal:  Oncoimmunology       Date:  2021-01-20       Impact factor: 7.723

Review 4.  TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.

Authors:  Jinah Yeo; Minkyung Ko; Dong-Hee Lee; Yoon Park; Hyung-Seung Jin
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-28

Review 5.  Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.

Authors:  Yu Yuan; Abdalla Adam; Chen Zhao; Honglei Chen
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

Review 6.  Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.

Authors:  Vincent Lemaire; Colby S Shemesh; Anand Rotte
Journal:  J Exp Clin Cancer Res       Date:  2021-10-01

7.  CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer.

Authors:  Ling Yi; Xin Jin; Jinghui Wang; Zhuohong Yan; Xu Cheng; Tao Wen; Bin Yang; Xiaojue Wang; Nanying Che; Zhidong Liu; Hongtao Zhang
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561

Review 8.  The changing role of natural killer cells in cancer metastasis.

Authors:  Isaac S Chan; Andrew J Ewald
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 14.808

9.  TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer.

Authors:  Yaping Chen; Hao Huang; Yuan Li; Wenlu Xiao; Yingting Liu; Rongzhang Chen; Yulan Zhu; Xiao Zheng; Changping Wu; Lujun Chen
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

10.  Expression of Membranous CD155 Is Associated with Aggressive Phenotypes and a Poor Prognosis in Patients with Bladder Cancer.

Authors:  Kohei Mori; Kazumasa Matsumoto; Noriyuki Amano; Dai Koguchi; Soichiro Shimura; Masahiro Hagiwara; Yuriko Shimizu; Masaomi Ikeda; Yuichi Sato; Masatsugu Iwamura
Journal:  Cancers (Basel)       Date:  2022-03-19       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.